Patent details

EP1895005 Title: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

Basic Information

Publication number:
EP1895005
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP070210471
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
French Title of Invention:
Inhibiteurs peptidiques à perméabilité cellulaire du processus de transduction du signal de JNK
German Title of Invention:
Zelldurchlässige Peptidhemmer des JNK-Signaltransduktionsweges
SPC Number:

Dates

Filing date:
12/10/2000
Grant date:
26/07/2017
EP Publication Date:
05/03/2008
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
26/07/2017
EP B1 Publication Date:
26/07/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
12/10/2017
Expiration date:
12/10/2020
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
26/07/2017
 
 

Name:
Xigen Inflammation Ltd.
Address:
Arch. Makariou III 195 Neocleous House, 3030 Limassol, Cyprus (CY)

Inventor

Name:
Bonny, Christophe
Address:
Switzerland (CH)

Priority

1

Priority Number:
158774 P
Priority Date:
12/10/1999
Priority Country:
United States (US)

2

Priority Number:
503954
Priority Date:
14/02/2000
Priority Country:
United States (US)

Classification

IPC classification:
A61K 38/00; C07K 14/47;

Publication

European Patent Bulletin

Issue number:
201730
Publication date:
26/07/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
28/02/2018 Outgoing Correspondence 1